Clinical trial
Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related…
NCT00473928 · Potentia Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00473928 |
|---|---|
| Title | Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) |
| Official title | Assessment of Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) |
| Acronym | ASaP |
| Lead sponsor | Potentia Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Age-Related Macular Degeneration |
| Intervention type | Drug |
| Interventions | POT-4 |
| Enrollment | 27 |
| Start date | May 1, 2007 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | May 16, 2007 |
| Last update posted | Mar 18, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: